Vnitr Lek 2006, 52(6):571-576

Obesity and progression of chronic renal insufficiency: a Czech long term prospective double-blind randomised multicentre study

V. Teplan1,2,*, O. Schück1,2, V. Hanzal1, J. Hajný3, M. Horáčková4, M. Ryba5, I. Staněk6, S. Šurel7, M. Bret8, M. Štollová1, D. Sasaková1
1 Klinika nefrologie, Transplantační centrum IKEM, přednosta prof. MUDr. Vladimír Teplan, DrSc.
2 Subkatedra nefrologie IPVZ, Praha, vedoucí prof. MUDr. Vladimír Teplan, DrSc.
3 HDS Chrudim, vedoucí lékař MUDr. Jan Hajný
4 Interní klinika 2. lékařské fakulty UK a FN v Motole, Praha, přednosta doc. MUDr. Milan Kvapil, CSc.
5 Krajská nemocnice Liberec, Department č. l, vedoucí MUDr. Pavel Lang
6 Interní oddělení Nemocnice České Budějovice, přednosta prim. MUDr. Pavel Havránek
7 Interní gastroenterologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Petr Dítě, DrSc.
8 Interní oddělení NsP Česká Lípa, přednosta prim. MUDr. Romana Balková

Obesity represents one of serious risk factors in chronic renal failure patients (CRF). In three years prospective double-blind randomised multicentre study we monitored 66 patients with advanced chronic renal insufficiency, GFR 24.4-37.3 ml/min (0.41 to 0.62 ml/s) and BMI ≥ 30 kg/m2 on long term low-protein diet (0.6 P/kg BW/day) and ACEI + ARB. Thirty four randomly selected patients (group I) were treated with keto amino acids, 32 patients in control group (group II) with placebo. During the study period significant decrease of BMI, proteinuria and slowing in progression of renal failure (Cin) were found. Significant changes were also noted in parameters of albumin and transferrin (p < 0.02), leucin and WQ (p < 0.01 - p < 0.02), glycaemia and HbA1c (p < 0.02), triglycerides (p < 0.01), leptin and ObRe (p < 0.01) and selected parameters of endothelial dysfunction (ET1, p < 0.02, TGFβ1, p < 0.02). Significantly also decreased PTH value (p < 0.01). Successful treatment of obesity can significantly improve long term prognosis in CRF patients.

Keywords: obesity; renal insufficiency; keto amino acids; progression

Received: November 7, 2005; Accepted: February 14, 2006; Published: June 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Teplan V, Schück O, Hanzal V, Hajný J, Horáčková M, Ryba M, et al.. Obesity and progression of chronic renal insufficiency: a Czech long term prospective double-blind randomised multicentre study. Vnitr Lek. 2006;52(6):571-576.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lachmanová J. Statistická ročenka dialyzační léčby v České republice. Praha: Česká nefrologická společnost 2004.
    2. Praga M. Obesity - a neglected culprit in renal disease. Nephrol Dial Transpl 2002; 17: 1157-1159. Go to original source... Go to PubMed...
    3. Kambham N, Markowitz GS, Valeri AM et al. Obesity - related glomerulopathy: An emerging epidemic. Kidney Int 2001; 59: 1498-1509. Go to original source... Go to PubMed...
    4. Klassen A, Sebekova K, Heidland A et al. Obesity - a neglected risk factor of the Kidney. Nieren und Hochdruckkrankheiten 2003; 32: 189-196.
    5. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112: 1785-1788. Go to original source... Go to PubMed...
    6. Agnami S, Vachharajani VT, Gupta R et al. Does treating obesity stabilize chronic kidney disease? BMC Nephrology 2005; 6: 1-4. Go to original source... Go to PubMed...
    7. Pelikánová T. Metabolický syndrom. Vnitř Lék 2003; 49: 900-906. Go to PubMed...
    8. Wiecek A, Kokot F, Chudek J et al. The adipose tissue - a novel endocrine organ of interest to the nephrologist. Nephrol Dial Transpl 2002; 17: 191-195. Go to original source... Go to PubMed...
    9. Axelsson J, Heimbürger O, Lindholm B et al. Adipose lissue and its relation to inflammation the role of adipokines. J Renal Nutr 2005; 15: 131-136. Go to original source... Go to PubMed...
    10. Stenvinkel P, Marchlewska A, Pecoits-Filho R et al. Adiponectin in renal disease: Relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 2004; 65: 274-281. Go to original source... Go to PubMed...
    11. Andrlová K, Haluzík M. Tuková tkáň a insulinová rezistence. Diab Met Endrokrin Výživa 2005; 8: 87-96.
    12. Zoccali C, Mallamaci F, Panuccio V et al. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int 2003; 63(Suppl 84): 98-102. Go to original source... Go to PubMed...
    13. Zoccali C, Mallamaci F, Tripetpi G. Adipose tissue as a source of inflammatory cytokines in health and disease: focus and-stage renal disease. Kidney Int 2003; 63(Suppl 84): 65-68. Go to original source... Go to PubMed...
    14. Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role: In the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830. Go to original source... Go to PubMed...
    15. Olšovský J. Obezita a diabetes. Vnitř Lék 2003; 49: 956-957. Go to PubMed...
    16. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119. Go to original source...
    17. Mitch W. Are supplements of ketoacids and amino acids useful in treating patients with chronic renal failure? Wien Klin Wocheschr 2000; 112: 863-864.
    18. Teplan V, Schück O, Horačková M at al. Effect of keto acid-amino acid supplement on the metabolism and renal elimination of branched-chain amino acids in patients with chronic renal insufficiency on a low protein diet. Wien Klin Wochenschr 2000; 112: 876-881.
    19. Teplan V, Schück O, Votruba M at al. Metabolic effect of keto acid-amino acid supplementation in patients with chronic renal insufficiency receiving a low-protein diet and recombinant human erythropoetin - A randomized controlled trial. Wien Klin Wochenschr 2001; 113: 661-669.
    20. Teplan V, Schück O, Knotek A et al. Enhanced metabolic effect of erythropoetin and keto acids in CRF patients on low-protein diet: Czech multicenter study. Am J Kidney Dis 2003; 41: Suppl 1: 26-30. Go to original source... Go to PubMed...
    21. Di Iorio BR, Minutolo R, de Nicola LD et al. Supplemented very low protein diet ameliorates responsiveness to erythropoetin in chronic renal failure. Kidney Int 2003; 64: 1822-1828. Go to original source... Go to PubMed...
    22. Meloni C, Taangelo P, Cipriani S et al. Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure. J Ren Nutr 2004; 14: 208-213. Go to original source... Go to PubMed...
    23. Prakash S, Prasad Pande D, Sharma S et al. Randomized, double-blind, placebo-controlled trial to evaluate efficacy of keto diet in predialytic chronic renal failure. J Ren Nutr 2004; 14: 89-96. Go to original source... Go to PubMed...
    24. Teplan V. Pharmacological features of keto amino acid therapy. Am J Nephrol 2005; 25(Suppl 1): 13-14.
    25. Chauveau P, Vendrely B, Haggan W et al. Body composition of patients on a very low-protein diet: a two-year survey with DEXA. J. Ren Nutr 2003; 4: 282-287. Go to original source... Go to PubMed...
    26. Schück O, Teplan V, Štollová M et al. Estimation of glomerular filtration rate in obese patients with chronic renal impairment based on serum cystatin C levels. Clin Nephrol 2004; 62: 92-96. Go to original source... Go to PubMed...
    27. Clinical Practice guidelines for chronic kidney disease (K/DOQI) National Kidney Foundation. New York 2002.
    28. Schück O, Smrčková J, Teplan V et al. Nová metoda stanovení glomerulární filtrace na podkladě sérové koncentrace kreatininu, močoviny a albumimu (MDRD). Vnitř Lék 2004; 50: 507-509. Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.